10-Q: TG Therapeutics Reports Profitable First Quarter 2025 Driven by BRIUMVI Sales

Sentiment:

Quarterly Report 9 May 2025 4:31 PM

TG Therapeutics achieves profitability in Q1 2025, driven by strong sales of BRIUMVI, its multiple sclerosis treatment.

Better than expectedThe company achieved a net income of $5.060 million compared to a net loss of $10.707 million in the same period last year.Product revenue from BRIUMVI sales in the U.S. increased to $119.655 million compared to $50.488 million in the same period last year.

Summary

TG Therapeutics reports a profitable first quarter in 2025, with net income of $5.06 million.
Product revenue, primarily from BRIUMVI sales in the U.S., reached $119.655 million, compared to $50.488 million in Q1 2024.
License, milestone, royalty and other revenue totaled $1.201 million, down from $12.986 million in the same period last year.
Research and development expenses increased to $46.362 million from $32.722 million year-over-year.
Selling, general and administrative expenses also rose to $50.331 million from $34.581 million.
The company's cash and cash equivalents, and short-term investment securities totaled $276.2 million as of March 31, 2025.
TG Therapeutics anticipates sufficient liquidity for more than a twelve-month period from the date of filing this Quarterly Report on Form 10-Q.
The company repurchased 199,965 shares of common stock at a cost of $6.1 million during the quarter.
The company is actively evaluating subcutaneous ublituximab with an expected dosing frequency of at least every other month.
The company is also evaluating azer-cel for the treatment of primary progressive MS.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with the company achieving profitability and strong revenue growth. While there are risks associated with drug development and commercialization, the overall tone is optimistic.

Positives

The company achieved profitability in Q1 2025, indicating successful commercialization of BRIUMVI.
Significant increase in product revenue from BRIUMVI sales demonstrates growing market acceptance.
Strong cash position provides financial flexibility for ongoing operations and future development.
Share repurchase program signals management's confidence in the company's future prospects.
Advancement of subcutaneous ublituximab and azer-cel programs indicates continued focus on innovation.

Negatives

License, milestone, royalty and other revenue decreased compared to the same period last year.
Research and development expenses increased, reflecting ongoing investment in clinical programs.
Selling, general and administrative expenses also increased, driven by commercialization activities.

Risks

The company's future profitability depends on sustained revenue generation from BRIUMVI and successful commercialization of other drug candidates.
Clinical trials may face delays or produce unfavorable results, impacting regulatory approval timelines.
The company relies on third-party manufacturers and suppliers, which could lead to supply chain disruptions.
The company faces competition from other pharmaceutical companies in the MS market.
The company is subject to various healthcare laws and regulations, and failure to comply could result in penalties.

Future Outlook

TG Therapeutics anticipates that its cash, cash equivalents, and investment securities, combined with projected revenues from BRIUMVI in the U.S. and ex-U.S., will provide sufficient liquidity for more than a twelve-month period from the date of filing this Quarterly Report on Form 10-Q.

Industry Context

The report reflects the competitive landscape of the biopharmaceutical industry, particularly in the multiple sclerosis market, where TG Therapeutics faces competition from established pharmaceutical companies and emerging therapies. The company's focus on commercializing BRIUMVI and developing innovative treatments like subcutaneous ublituximab and azer-cel aligns with industry trends towards personalized medicine and improved patient outcomes.

Comparison to Industry Standards

Comparing TG Therapeutics' performance to industry standards requires considering companies with similar market capitalization and focus on multiple sclerosis treatments.
Companies like Biogen, Novartis, and Roche have established MS franchises and serve as benchmarks for commercial success.
Biogen's Tecfidera and Novartis' Gilenya are oral MS therapies that compete with BRIUMVI, while Roche's Ocrevus is an IV-administered anti-CD20 antibody.
TG Therapeutics' Q1 2025 revenue of $119.655 million from BRIUMVI sales is a positive indicator, but it's essential to compare its market share and growth trajectory against these established players.
The development of subcutaneous ublituximab aims to improve convenience and potentially expand market reach, aligning with industry trends towards patient-centric drug delivery.
The azer-cel program for progressive MS represents a novel approach and could differentiate TG Therapeutics from competitors focused on relapsing forms of the disease.
However, the success of azer-cel will depend on clinical trial outcomes and regulatory approval, which are subject to inherent risks.

Related Party Transactions

In July 2015, we entered into a Shared Services Agreement (the Shared Services Agreement) with FBIO to share the cost of certain services such as facilities use, personnel costs and other overhead and administrative costs.

Stakeholder Impact

Shareholders: Positive impact due to profitability and share repurchase program.
Employees: Potential for growth and development with the company's expansion.
Patients: Access to innovative treatments for multiple sclerosis.
Suppliers: Continued business relationships with the company.
Creditors: Increased financial stability and ability to meet debt obligations.

Next Steps

Continue commercialization efforts for BRIUMVI in the U.S. and European markets.
Advance clinical development programs for subcutaneous ublituximab and azer-cel.
Monitor and manage expenses to maintain profitability.
Evaluate potential strategic collaborations and acquisitions.

Key Dates

Date	Description
2010-03-31	Date of merger between Manhattan Pharmaceuticals, Inc. and Ariston Pharmaceuticals, Inc.
2012-01-01	Effective date of exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC relating to the development of ublituximab.
2012-12-01	Date of exclusive sublicense agreement with Ildong Pharmaceutical Co. Ltd. relating to the development and commercialization of ublituximab in South Korea and Southeast Asia.
2014-10-01	Date of Office Agreement with Fortress Biotech, Inc.
2019-02-28	Date used for incremental borrowing rate of 10.25% for operating leases that commenced prior to that date through December 31, 2021.
2021-10-01	Date of five-year lease for office space in North Carolina (the NC Lease).
2022-09-02	Date of filing of automatic shelf registration statement on Form S-3 (the 2022 WKSI Shelf).
2022-12-28	FDA approval of BRIUMVI for the treatment of RMS.
2023-01-26	U.S. commercial launch of BRIUMVI.
2023-03-31	Date of First Amendment to the Amended Loan Agreement with Hercules.
2023-06-01	European Commission (EC) granted approval of BRIUMVI for the treatment of adult patients with RMS who have active disease defined by clinical or imaging features.
2023-07-28	Date of Commercialization Agreement with Neuraxpharm.
2023-08-01	Agreement with Neuraxpharm Pharmaceuticals, S.L. (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of CNS disorders, for the Ex-U.S. commercialization of BRIUMVI (Commercialization Agreement).
2023-11-01	Approval by the MHRA for BRIUMVI to treat adult patients with RMS with active disease defined by clinical or imaging features in the UK.
2024-01-07	Date of Precision License Agreement with Precision BioSciences, Inc.
2024-02-01	Precision BioSciences, Inc. had a 30-to-1 reverse stock split in February 2024.
2024-02-26	Commercial launch of BRIUMVI in the EU by Neuraxpharm, with BRIUMVI made available for commercial sale in Germany.
2024-08-02	Date of term loan facility of $250 million (the Initial Term Loan) with Blue Owl Capital Corporation, as administrative agent (the Administrative Agent), HealthCare Royalty and Blue Owl Capital under the Financing Agreement.
2025-01-01	The Company made a one-time payment to Precision equal to $2.5 million (the Deferred Precision Stock Payment), as an equity investment, for the purchase of 220,712 shares of Precision common stock.
2025-02-10	The Company entered into the Strategic Platform License Agreement with MaxCyte, Inc.
2025-03-31	End of the quarterly period.
2025-05-05	There were 158,755,036 shares of the registrants common stock, $0.001 par value, outstanding as of May 5, 2025.

Keywords

BRIUMVI, ublituximab, multiple sclerosis, TGTX, TG Therapeutics, azer-cel, profitability, commercialization, clinical trials, pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.